Ranbaxy Laboratories Limited
http://www.ranbaxy.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ranbaxy Laboratories Limited
Sun Signs $485m Settlement Deal To Close Out Ranbaxy Antitrust Case
India’s Sun Pharma is set to hand over almost half-a-billion dollars to resolve claims that its Ranbaxy unit schemed to delay the launch of generic versions of three popular prescription drugs. The firm has denied all allegations as part of the deal, which must be signed off by a US district court.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.